Sunday 11 October 2026 Export all SNY data to Excel Powerpack

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

40.07 0.16 −0.40%
Market cap
$95.9B
P/E
21.0×
Fwd P/E
—
Dividend yield
6.05%
F-score
7/9
Altman Z
2.50
Beneish M
−2.63
Dividend safety
58/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 — 7 —

+8 more TTM periods

ROE
5.87% 0.00% 10.94% 0.00%
ROA
3.21% 6.06% 6.16% 7.01%
ROIC
6.58% 6.12% 6.57% 6.17%
Return on Tangible Assets
40.46% 72.55% 61.72% 75.08%
Average Days of Receivables
68.60 3.75 68.81 4.53
Free Cash Flow per Share
6.08 0.00 7.62 0.00
Free Cash Flow
14,542.46 — 18,607.12 —
Other line items

Show all line items

Columns are period end dates